Payment overview · 2025
General Payments
$32,222.33
82 reported records · 15 companies
Healthcare provider profile · identity verified
Kavi Krishna Devulapalli, MD
Allopathic & Osteopathic Physicians|Radiology|Vascular & Interventional Radiology · COLUMBIA, MO · NPI 1881950749
Verified facts
What the public records show
CMS Open Payments records show Kavi Krishna Devulapalli, MD received $32,222.33 in general payments during 2025 across 82 reported records.
Terumo Medical Corporation accounted for 88.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $28,410.87 | 88.2% | 36 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,657.06 | 5.1% | 24 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $1,178.75 | 3.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $187.35 | 0.6% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $179.15 | 0.6% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $133.74 | 0.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $98.55 | 0.3% | 4 | 2025 |
| Koya Medical, Inc. | Unresolved — no canonical attribution shown | $77.41 | 0.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $77.00 | 0.2% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $76.76 | 0.2% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $62.08 | 0.2% | 3 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $30.00 | 0.1% | 2 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $24.03 | 0.1% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $15.00 | 0.1% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $14.58 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $24,250.00 | 13 |
| Travel and Lodging | $4,547.55 | 17 |
| Food and Beverage | $2,424.78 | 51 |
| Honoraria | $1,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROGREAT Normalized: progreat |
Device | Terumo Medical Corporation | $15,806.10 | 10 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $8,750.78 | 8 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $3,791.45 | 15 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $1,051.72 | 8 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $235.30 | 5 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $187.35 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $179.15 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $154.19 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $133.74 | 1 | 2025 |
Source payment records
|
|||||
| FUSION Normalized: fusion |
Device | Medtronic, Inc. | $121.58 | 6 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $98.55 | 4 | 2025 |
Source payment records
|
|||||
| Asahi Interventional Radiology Wires Normalized: asahi interventional radiology wires |
Device | ASAHI INTECC USA, INC. | $96.80 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $81.95 | 1 | 2025 |
Source payment records
|
|||||
| DAYSPRING Normalized: dayspring |
Device | Koya Medical, Inc. | $77.41 | 1 | 2025 |
Source payment records
|
|||||
| KOYA MEDICAL Normalized: koya medical |
Device | Koya Medical, Inc. | $77.41 | 1 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $77.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $76.76 | 1 | 2025 |
Source payment records
|
|||||
| HYDROPEARL Normalized: hydropearl |
Device | Terumo Medical Corporation | $75.62 | 4 | 2025 |
Source payment records
|
|||||
| GLIDEWIRE Normalized: glidewire |
Device | Terumo Medical Corporation | $66.16 | 3 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| OSTEOCOOL RF ABLATION SYSTEM Normalized: osteocool rf ablation system |
Device | Medtronic, Inc. | $35.50 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ANGIODYNAMICS Normalized: angiodynamics |
Device | AngioDynamics, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32,222.33 · 82 records | Terumo Medical Corporation | ANGIODYNAMICS, APLIGRAF, AZUR CX DETACHABLE, Asahi Coronary Wires, Asahi Interventional Radiology Wires, Asahi Peripheral Vascular Wires, CLOT MANAGEMENT, DAYSPRING, ENDURANT IIS, ESPRIT, FUSION, GLIDESHEATH SLENDER, GLIDEWIRE, GORE VIABAHN Endoprosthesis with Heparin, HYDROPEARL, INCEPTIV, INTELLIS ADAPTIVESTIM, JOURNAVX, KOYA MEDICAL, KYPHON EXPRESS II KYPHOPAK TRAY, MYNX CONTROL, NAVICROSS, OSTEOCOOL RF ABLATION SYSTEM, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, PROGREAT, PURAPLY WOUND MATRIX, Peripheral Vascular Undivided, SYNCHROMEDII, Senza, Venovo | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error